Literature DB >> 21316097

Cardiovascular safety and diabetes drug development.

Daniel J Drucker1, Allison B Goldfine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21316097     DOI： 10.1016/S0140-6736(10)62299-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  Clinical impact of oral antidiabetic medications in heart failure patients.

Authors:  Alberto Palazzuoli; Elena Ceccarelli; Gaetano Ruocco; Ranuccio Nuti
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 2.  New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease.

Authors:  Malak Almutairi; Jordan S F Chan; John R Ussher
Journal:  Front Physiol       Date:  2022-06-27       Impact factor: 4.755

3.  Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.

Authors:  Baptist Gallwitz
Journal:  Ther Adv Endocrinol Metab       Date:  2013-06       Impact factor: 3.565

Review 4.  Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.

Authors:  Cai Chen; Qilin Yu; Shu Zhang; Ping Yang; Cong-Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.

Authors:  Sanjoy K Paul; Kerenaftali Klein; David Maggs; Jennie H Best
Journal:  Cardiovasc Diabetol       Date:  2015-01-24       Impact factor: 9.951

Review 6.  Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.

Authors:  Ling Li; Sheyu Li; Jiali Liu; Ke Deng; Jason W Busse; Per Olav Vandvik; Evelyn Wong; Zahra N Sohani; Malgorzata M Bala; Lorena P Rios; German Malaga; Shanil Ebrahim; Jiantong Shen; Longhao Zhang; Pujing Zhao; Qunfei Chen; Yingqiang Wang; Gordon H Guyatt; Xin Sun
Journal:  BMC Cardiovasc Disord       Date:  2016-05-11       Impact factor: 2.298

Review 7.  The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy.

Authors:  Keshav Gopal; Jadin J Chahade; Ryekjang Kim; John R Ussher
Journal:  Front Physiol       Date:  2020-12-07       Impact factor: 4.566

8.  Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Authors:  Janet B McGill; Lance Sloan; Jennifer Newman; Sanjay Patel; Christophe Sauce; Maximilian von Eynatten; Hans-Juergen Woerle
Journal:  Diabetes Care       Date:  2012-10-01       Impact factor: 19.112

9.  The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.

Authors:  Laurie L Baggio; John R Ussher; Brent A McLean; Xiemin Cao; M Golam Kabir; Erin E Mulvihill; Alexandra S Mighiu; Hangjun Zhang; Andreas Ludwig; Randy J Seeley; Scott P Heximer; Daniel J Drucker
Journal:  Mol Metab       Date:  2017-09-01       Impact factor: 7.422

10.  Immunomodulator FTY720 improves glucose homeostasis and diabetic complications by rejuvenation of β-cell function in nonhuman primate model of diabetes.

Authors:  Yixin Jim Wang; Xiaoli Wang; Annie An; Mingfa Zang; Ling Xu; Kefeng Gong; Weihua Song; Qing Li; Xiaojun Lu; Yong-Fu Xiao; Guoliang Yu; Zhongmin A Ma
Journal:  Fundam Clin Pharmacol       Date:  2022-02-02       Impact factor: 2.747
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.